Her-2 negative esophagogastric adenocarcinoma
Showing 1 - 25 of >10,000
Gastroesophageal Adenocarcinoma Trial (toripalimab FOLFOX)
Not yet recruiting
- Gastroesophageal Adenocarcinoma
- toripalimab FOLFOX
- (no location specified)
Aug 3, 2023
Neoadjuvant Chemotherapy and Immunotherapy for HER2(-),pMMR
Recruiting
- Gastric Cancer
- SOX plus Paclitaxel(albumin-bound) followed by PD-1 antibody
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Sep 12, 2022
Esophagogastric Adenocarcinoma Trial (Pembrolizumab, Trastuzumab, FLOT)
Not yet recruiting
- Esophagogastric Adenocarcinoma
- Pembrolizumab
- +2 more
- (no location specified)
Aug 17, 2022
Esophagogastric Cancer, HER2-Negative Trial in United States (regorafenib, nivolumab, FOLFOX chemo with oxaliplatin)
Active, not recruiting
- Esophagogastric Cancer
- HER2-Negative
- regorafenib
- +2 more
-
Basking Ridge, New Jersey
- +6 more
Nov 23, 2022
Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer Trial in China
Not yet recruiting
- Adenocarcinoma of the Stomach
- +2 more
- Toripalimab
- +2 more
-
Hangzhou, Zhejiang, China
- +7 more
Feb 7, 2023
Esophagogastric Adenocarcinoma Trial (Sacituzumab govitecan)
Not yet recruiting
- Esophagogastric Adenocarcinoma
- Sacituzumab govitecan
- (no location specified)
Nov 9, 2023
Adenocarcinoma - GEJ, Adenocarcinoma of the Stomach Trial in Bengbu (HER2 Tumor Vaccine, HER2 Tumor Vaccine+ Standard of Care
Recruiting
- Adenocarcinoma - GEJ
- Adenocarcinoma of the Stomach
- HER2 Tumor Vaccine
- HER2 Tumor Vaccine+ Standard of Care chemotherapy
-
Bengbu, Anhui, ChinaFirst Affiliated Hospital Bengbu Medical College
Apr 6, 2022
HER-2 Expression in Pancreatic Duct Adenocarcinoma
Completed
- Pancreatic Adenocarcinoma
- immunohistochemical approach
- (no location specified)
Sep 20, 2023
Esophageal Cancer, Gastric Adenocarcinoma, HER2 Gene Mutation Trial in United States (Pembrolizumab, Trastuzumab)
Not yet recruiting
- Esophageal Cancer
- +2 more
-
Baltimore, Maryland
- +8 more
Nov 3, 2023
Gastric Cancer Trial in China (Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab)
Recruiting
- Gastric Cancer
- Experimental dose: modified XELOX + sintilimab
- Standard dose: standard XELOX + sintilimab
-
Guangzhou, Guangdong, China
- +9 more
Jun 23, 2023
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/
Not yet recruiting
- HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- SHR-A1811
- Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
- (no location specified)
Nov 6, 2023
Breast Cancer Trial in Beijing (Mitoxantrone HCl liposome, Capecitabine)
Not yet recruiting
- Breast Cancer
- Mitoxantrone hydrochloride liposome
- Capecitabine
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Dec 1, 2023
Stomach Tumors, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Atezolizumab, Tiragolumab, Oxaliplatin)
Active, not recruiting
- Stomach Neoplasms
- +2 more
- Atezolizumab
- +3 more
-
Beijing, China
- +10 more
Dec 21, 2022
HER2-low in Unresectable and/or Metastatic Breast Cancer
Not yet recruiting
- Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2
- (no location specified)
Nov 6, 2023
Gastroesophageal Adenocarcinoma Trial (Paclitaxel, Ramucirumab, Zanidatamab)
Not yet recruiting
- Gastroesophageal Adenocarcinoma
- Paclitaxel
- +2 more
- (no location specified)
Sep 12, 2023
HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)
Not yet recruiting
- HER2-positive Advanced Gastric Cancer
- HER2-positive Gastroesophageal Junction Adenocarcinoma
- Trastuzumab deruxtecan
- (no location specified)
Aug 11, 2023
HER2-low in Metastatic Breast Cancer Patients
Not yet recruiting
- HER2-negative
- (no location specified)
Nov 9, 2023
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;
Recruiting
- Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
- dalpiciclib; fluvestrant; compound gossypol acetate tablets
-
Hangzhou, Zhejiang, ChinazhejiangCH
Nov 9, 2023
Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)
Recruiting
- Her-2 Negative Breast Cancer
- HRR Gene Mutation
- Camrelizumab
- +2 more
-
Guangzhou, Guangdong, ChinaFirst Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer, Locally Advanced Unresectable Gastric
Available
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer
- +3 more
-
Morristown, New JerseyAMG Hematology/Oncology
Sep 15, 2023
Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer
Active, not recruiting
- Hormone-receptor-positive Breast Cancer
- +2 more
- No drug
-
Cambridge, MassachusettsConcertAI database
Sep 8, 2023
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,
Not yet recruiting
- HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
- PERT-IJS plus trastuzumab, carboplatin and docetaxel
- Perjeta plus trastuzumab, carboplatin and docetaxel
- (no location specified)
Sep 21, 2023